Thc Therapeutics Inc Financials
This page shows Thc Therapeutics Inc (THCT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Thc Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Thc Therapeutics Inc carries a low D/E ratio of -1.00, meaning only $-1.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 95/100, indicating a strong balance sheet with room for future borrowing.
Thc Therapeutics Inc's current ratio of 0.00 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Key Financial Metrics
Earnings & Revenue
Thc Therapeutics Inc generated $0 in revenue in fiscal year 2024.
Cash & Balance Sheet
Thc Therapeutics Inc held $35 in cash against $0 in long-term debt as of fiscal year 2024.
Thc Therapeutics Inc had 40M shares outstanding in fiscal year 2024. This represents an increase of 22.8% from the prior year.
Margins & Returns
Capital Allocation
THCT Income Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Cost of Revenue | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Gross Profit | N/A | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $9K+24.2% | $7K+465.9% | $1K | N/A | $3K-94.1% | $58K+644.6% | $8K |
| Operating Income | N/A | N/A | N/A | -$55K | N/A | -$58K | N/A | -$108K |
| Interest Expense | N/A | $18K-6.8% | $20K+1.5% | $19K | N/A | $19K-4.2% | $20K-0.3% | $20K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
THCT Balance Sheet
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11K-9.9% | $12K-20.3% | $15K+27.0% | $12K-10.2% | $13K-2.7% | $13K-42.0% | $23K-59.3% | $57K |
| Current Assets | $35-95.9% | $849-75.8% | $4K+35010.0% | $10-99.0% | $980-0.5% | $985-90.5% | $10K-76.3% | $44K |
| Cash & Equivalents | $35-95.9% | $849-75.8% | $4K+35010.0% | $100.0% | $10-33.3% | $15-99.8% | $9K+148.1% | $4K |
| Inventory | N/A | N/A | N/A | $0 | $0 | $0 | $0 | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.8M+7.9% | $3.5M-9.7% | $3.9M+15.5% | $3.4M+1.8% | $3.3M+1.0% | $3.3M-3.1% | $3.4M-35.7% | $5.3M |
| Current Liabilities | $3.8M+11.1% | $3.4M-9.9% | $3.8M+16.0% | $3.3M-1.2% | $3.3M+4.2% | $3.2M-3.2% | $3.3M-36.4% | $5.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$3.8M-8.0% | -$3.5M+9.6% | -$3.9M-15.5% | -$3.4M-1.9% | -$3.3M-1.0% | -$3.3M+2.8% | -$3.4M+35.5% | -$5.2M |
| Retained Earnings | -$39.2M-0.7% | -$39.0M+0.3% | -$39.1M-1.5% | -$38.5M-0.2% | -$38.4M-0.1% | -$38.4M+0.2% | -$38.5M+4.2% | -$40.2M |
THCT Cash Flow Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$814 | N/A | -$45K-16676.2% | -$269-472.3% | -$47+97.8% | -$2K+96.5% | -$62K-187.3% | -$21K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $0 | N/A | $49K+17977.7% | $269+540.5% | $42+100.6% | -$7K-109.9% | $67K+167.8% | $25K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
THCT Financial Ratios
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.01 |
| Debt-to-Equity | -1.000.0 | -1.000.0 | -1.000.0 | -1.000.0 | -1.000.0 | -1.000.0 | -1.010.0 | -1.01 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$3.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Thc Therapeutics Inc's annual revenue?
Thc Therapeutics Inc (THCT) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
What are Thc Therapeutics Inc's total assets?
Thc Therapeutics Inc (THCT) had $11K in total assets as of fiscal year 2024, including both current and long-term assets.
What is Thc Therapeutics Inc's current ratio?
Thc Therapeutics Inc (THCT) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Thc Therapeutics Inc's debt-to-equity ratio?
Thc Therapeutics Inc (THCT) had a debt-to-equity ratio of -1.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
Why is Thc Therapeutics Inc's debt-to-equity ratio negative or unusual?
Thc Therapeutics Inc (THCT) has negative shareholder equity of -$3.8M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
How financially healthy is Thc Therapeutics Inc?
Thc Therapeutics Inc (THCT) scores 16 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.